Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
👀 Bezos, Buffett & Berkowitz: What's in Their Portfolios? Unlock Data
Analysts positive on Biogen after FDA posts docs ahead of advisory panel for Tofersen
Published Mar 21, 2023 16:14
© Reuters
By Davit Kirakosyan
FDA posted documents yesterday ahead of the advisory panel for Biogen's (NASDAQ:BIIB) Tofersen for ALS.
Needham believes these documents strike a favorable tone and the FDA appears to be leaning towards approving Tofersen for SOD1-ALS.
“What we did not expect, but we believe indicates the FDA is positively inclined on approval is that while Tofersen was submitted under the accelerated approval pathway, it appears the FDA is seeking the AdCom's input on whether to grant Tofersen either accelerated or traditional approval,” said the firm.
Regardless of the outcome of the March 22 meeting, Needham believes Tofersen is not expected to significantly affect the stock price. However, they noted that these developments are an overall positive for the CNS space, which has seen recent approvals granted under a more flexible purview.
Meanwhile, BofA Securities reiterated its Neutral rating and $295 price target on the stock, noting that the FDA briefing document suggests Tofersen approval is likely given the unmet needs and there's a suggestive treatment effect.
Overall, while it remains to be seen how the AdCom will vote and the eventual FDA decision, the firm said it wouldn’t be surprised to see a positive vote for Tofersen.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.